Search Page

1

Cite

Share

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.

Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Among authors: moua t. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.

Cite

Share

2

Cite

Share

Treatment of acute exacerbations of interstitial lung disease.

Azadeh N, Moua T, Baqir M, Ryu JH. Azadeh N, et al. Among authors: moua t. Expert Rev Respir Med. 2018 Apr;12(4):309-313. doi: 10.1080/17476348.2018.1446831. Epub 2018 Mar 12. Expert Rev Respir Med. 2018. PMID: 29486130 Review.

Cite

Share

3

Cite

Share

Pulmonary mucormycosis: clinical features and outcomes.

Lin E, Moua T, Limper AH. Lin E, et al. Among authors: moua t. Infection. 2017 Aug;45(4):443-448. doi: 10.1007/s15010-017-0991-6. Epub 2017 Feb 20. Infection. 2017. PMID: 28220379

Cite

Share

4

Cite

Share

Treatment of the Connective Tissue Disease-Related Interstitial Lung Diseases: A Narrative Review.

Gao Y, Moua T. Gao Y, et al. Among authors: moua t. Mayo Clin Proc. 2020 Mar;95(3):554-573. doi: 10.1016/j.mayocp.2019.07.007. Mayo Clin Proc. 2020. PMID: 32138882 Review.

Cite

Share

5

Cite

Share

Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.

Lee AS, Scofield RH, Hammitt KM, Gupta N, Thomas DE, Moua T, Ussavarungsi K, St Clair EW, Meehan R, Dunleavy K, Makara M, Carsons SE, Carteron NL; Consensus Expert Panel (CEP) Members. Lee AS, et al. Among authors: moua t. Chest. 2021 Feb;159(2):683-698. doi: 10.1016/j.chest.2020.10.011. Epub 2020 Oct 16. Chest. 2021. PMID: 33075377 Free article.

Cite

Share

6

Cite

Share

Amyloid in the Lung.

Baqir M, Roden AC, Moua T. Baqir M, et al. Among authors: moua t. Semin Respir Crit Care Med. 2020 Apr;41(2):299-310. doi: 10.1055/s-0040-1708059. Epub 2020 Apr 12. Semin Respir Crit Care Med. 2020. PMID: 32279300 Review.

Cite

Share

7

Cite

Share

Response.

Moua T, Levin DL, Ryu JH. Moua T, et al. Chest. 2013 Jul;144(1):362. doi: 10.1378/chest.13-0942. Chest. 2013. PMID: 23880695 No abstract available.

Cite

Share

8

Cite

Share

Comparing effectiveness of prognostic tests in idiopathic pulmonary fibrosis.

Moua T, Lee AS, Ryu JH. Moua T, et al. Expert Rev Respir Med. 2019 Oct;13(10):993-1004. doi: 10.1080/17476348.2019.1656069. Epub 2019 Aug 26. Expert Rev Respir Med. 2019. PMID: 31405303 Review.

Cite

Share

9

Cite

Share

A Bodybuilder with Dyspnea and Hypercalcemia.

Colbenson GA, Dempsey TM, Cecchini MJ, Aubry MC, Moua T, Ryu JH. Colbenson GA, et al. Among authors: moua t. Am J Med. 2021 Jun;134(6):e363-e365. doi: 10.1016/j.amjmed.2020.10.043. Epub 2020 Dec 11. Am J Med. 2021. PMID: 33316251 No abstract available.

Cite

Share

10

Cite

Share

Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives.

Moua T, Ryu JH. Moua T, et al. Ther Clin Risk Manag. 2019 Jan 3;15:73-81. doi: 10.2147/TCRM.S160248. eCollection 2019. Ther Clin Risk Manag. 2019. PMID: 30655671 Free PMC article. Review.

Cite

Share